S. 4152 · 117th Congress
A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
- Stage
- In committee
- Sponsor
- Mark Kelly
- Introduced
- 2022-05-05
- Latest action
- 2022-05-05 · Introduced in Senate
Summary
This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.